BeiGene Future Growth
Future criteria checks 4/6
BeiGene is forecast to grow earnings and revenue by 66% and 19.1% per annum respectively. EPS is expected to grow by 68.7% per annum. Return on equity is forecast to be 13% in 3 years.
Key information
66.0%
Earnings growth rate
68.7%
EPS growth rate
Biotechs earnings growth | 40.3% |
Revenue growth rate | 19.1% |
Future return on equity | 13.0% |
Analyst coverage | Good |
Last updated | 18 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 5,597 | 366 | 390 | 741 | 25 |
12/31/2025 | 4,575 | -121 | -247 | 86 | 30 |
12/31/2024 | 3,622 | -637 | -511 | -321 | 30 |
6/30/2024 | 3,097 | -524 | -1,356 | -704 | N/A |
3/31/2024 | 2,763 | -784 | -1,566 | -902 | N/A |
12/31/2023 | 2,459 | -882 | -1,754 | -1,157 | N/A |
9/30/2023 | 2,204 | -959 | -1,853 | -1,254 | N/A |
6/30/2023 | 1,811 | -1,732 | -2,283 | -1,738 | N/A |
3/31/2023 | 1,557 | -1,917 | -2,298 | -1,824 | N/A |
12/31/2022 | 1,416 | -2,004 | -1,966 | -1,497 | N/A |
9/30/2022 | 1,250 | -2,149 | -2,144 | -1,686 | N/A |
6/30/2022 | 1,069 | -2,030 | -2,016 | -1,620 | N/A |
3/31/2022 | 877 | -1,960 | -2,044 | -1,660 | N/A |
12/31/2021 | 1,176 | -1,458 | -1,614 | -1,299 | N/A |
9/30/2021 | 1,062 | -1,340 | -1,334 | -1,123 | N/A |
6/30/2021 | 947 | -1,327 | -1,193 | -974 | N/A |
3/31/2021 | 863 | -1,167 | -1,030 | -816 | N/A |
12/31/2020 | 309 | -1,625 | -1,510 | -1,283 | N/A |
9/30/2020 | 266 | -1,512 | -1,426 | -1,218 | N/A |
6/30/2020 | 225 | -1,394 | -1,301 | -1,137 | N/A |
3/31/2020 | 402 | -1,145 | -1,093 | -920 | N/A |
12/31/2019 | 428 | -949 | -909 | -750 | N/A |
9/30/2019 | 430 | -829 | -876 | -677 | N/A |
6/30/2019 | 434 | -665 | -747 | -544 | N/A |
3/31/2019 | 244 | -737 | -787 | -615 | N/A |
12/31/2018 | 198 | -674 | -689 | -548 | N/A |
9/30/2018 | 158 | -505 | -344 | -260 | N/A |
6/30/2018 | 324 | -243 | -189 | -121 | N/A |
3/31/2018 | 271 | -147 | N/A | -56 | N/A |
12/31/2017 | 238 | -93 | N/A | 13 | N/A |
9/30/2017 | 220 | -31 | N/A | -107 | N/A |
6/30/2017 | N/A | -184 | N/A | -138 | N/A |
3/31/2017 | 0 | -148 | N/A | -105 | N/A |
12/31/2016 | 1 | -119 | N/A | -90 | N/A |
9/30/2016 | 6 | -109 | N/A | -80 | N/A |
6/30/2016 | 7 | -87 | N/A | -66 | N/A |
3/31/2016 | 8 | -69 | N/A | -56 | N/A |
12/31/2015 | 9 | -57 | N/A | -40 | N/A |
9/30/2015 | 6 | -34 | N/A | -34 | N/A |
6/30/2015 | 11 | -29 | N/A | -19 | N/A |
3/31/2015 | 12 | -26 | N/A | -11 | N/A |
12/31/2014 | 13 | -18 | N/A | -9 | N/A |
12/31/2013 | 11 | -7 | N/A | 4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6160 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 6160 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6160 is expected to become profitable in the next 3 years.
Revenue vs Market: 6160's revenue (19.1% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
High Growth Revenue: 6160's revenue (19.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6160's Return on Equity is forecast to be low in 3 years time (13%).